Telesis Bio, Inc. (TBIO)

USD 0.49

(-7.55%)

Long Term Debt Summary of Telesis Bio, Inc.

  • Telesis Bio, Inc.'s latest annual long term debt in 2023 was 5.26 Million USD , down -74.66% from previous year.
  • Telesis Bio, Inc.'s latest quarterly long term debt in 2024 Q1 was 5.22 Million USD , down -0.87% from previous quarter.
  • Telesis Bio, Inc. reported annual long term debt of 20.79 Million USD in 2022, up 34.28% from previous year.
  • Telesis Bio, Inc. reported annual long term debt of 15.48 Million USD in 2021, up 149.31% from previous year.
  • Telesis Bio, Inc. reported quarterly long term debt of 5.22 Million USD for 2024 Q1, down -0.87% from previous quarter.
  • Telesis Bio, Inc. reported quarterly long term debt of 40.94 Million USD for 2023 Q1, up 96.93% from previous quarter.

Annual Long Term Debt Chart of Telesis Bio, Inc. (2023 - 2016)

Historical Annual Long Term Debt of Telesis Bio, Inc. (2023 - 2016)

Year Long Term Debt Long Term Debt Growth
2023 5.26 Million USD -74.66%
2022 20.79 Million USD 34.28%
2021 15.48 Million USD 149.31%
2020 6.21 Million USD 33.35%
2019 4.65 Million USD 113.47%
2018 -34.58 Million USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%

Peer Long Term Debt Comparison of Telesis Bio, Inc.

Name Long Term Debt Long Term Debt Difference
Acutus Medical, Inc. 32.65 Million USD 83.864%
Biotricity, Inc. 10.85 Million USD 51.464%
Cell MedX Corp. - USD -Infinity%
Dynatronics Corporation 3.25 Million USD -61.701%
Nemaura Medical Inc. 3.08 Million USD -70.648%
PetVivo Holdings, Inc. 1.01 Million USD -418.128%
RetinalGenix Technologies Inc. - USD -Infinity%
Sonendo, Inc. 14.03 Million USD 62.458%
Talis Biomedical Corporation 16.78 Million USD 68.611%
Viveve Medical, Inc. 5.12 Million USD -2.83%